M1FG
NBIX icon

Mach-1 Financial Group’s Neurocrine Biosciences NBIX Stock Holding History

Mach-1 Financial Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,410
Closed -$496K – 256
2023
Q3 		$496K Buy
+4,410
New +$464K 0.21% 121
2023
Q1 		– Sell
-5,244
Closed -$626K – 315
2022
Q4 		$626K Buy
+5,244
New +$614K 0.21% 86

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Mach-1 Financial Group's NBIX Position: Q4 2023 in Review

Mach-1 Financial Group sold out of Neurocrine Biosciences (NBIX) in Q4 2023, closing a stake of 4,410 shares — an estimated $496K sold.

Mach-1 Financial Group first reported a position in NBIX in Q4 2022 and held it in 2 quarters. The position peaked at $626K in Q4 2022. 554 funds tracked by Wall St. Rank hold NBIX as of Q4 2023.

  • Mach-1 Financial Group reported no remaining Neurocrine Biosciences position as of Q4 2023 after selling out during the quarter.
  • Mach-1 Financial Group sold 4,410 Neurocrine Biosciences shares in Q4 2023, an estimated $496K.
  • Mach-1 Financial Group first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 2 quarters.
  • Mach-1 Financial Group's Neurocrine Biosciences position peaked at $626K in Q4 2022.
  • 554 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2023.

Based on Mach-1 Financial Group's 13F filing for Q4 2023, filed 5 Feb 2024.